Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05936970 · ClinicalTrials.gov registry record
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD
A clinical trial of Rheumatoid Arthritis, sponsored by Aqtual.
- Recruiting
- Registry status
- 1,410
- Enrollment target
- 1
- Study location
NCT05936970: Recruiting study of Rheumatoid Arthritis, sponsored by Aqtual.
NCT05936970 is a study of Rheumatoid Arthritis that is actively recruiting participants, run by Aqtual. The registered enrollment target is 1,410 participants, below the 4,683-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05936970, a study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Aqtual.
- RECRUITING
- Registry status
- 1,410 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.
Primary Outcome
This study aims to identify cfDNA signatures that predict response to specific bDMARD or tsDMARD therapies for RA treatment.
Conditions Studied
Study Locations (1)
North Carolina
- Arthritis and Osteoporosis Consultants of the Carolinas - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,410 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2025-12 |
What NCT05936970 shows while recruiting
NCT05936970 is an observational study that tracks outcomes without assigning an intervention. Its 1,410 participants enrollment target places it among the larger protocols in the corpus, below the 4,683-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT05936970 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05936970 about?
NCT05936970 is a clinical study titled "Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD". The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.
What is the current status of trial NCT05936970?
This trial is currently recruiting. The enrollment target is 1,410 participants. The study started on 2023-06-29. Estimated completion is 2025-12.
What conditions does trial NCT05936970 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
Who is sponsoring clinical trial NCT05936970?
This trial is sponsored by Aqtual, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05936970 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05936970's enrollment target sits among peer trials
1,410 16th of 197 higher than 182 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI